April 20th, 2015
This week’s topics include the efficacy and safety of both alirocumab and evolocumab in reducing lipids and CV events, survival and outcomes following bioprosthetic vs. mechanical mitral valve replacement, and more.
March 15th, 2015
New information emerged today about two new cholesterol-lowering drugs that have been attracting a lot of attention. Data about the PCSK9 inhibitors — evolocumab, under development by Amgen, and alirocumab, under development by Sanofi and Regeneron — were presented at the American College of Cardiology meeting in San Diego and published simultaneously in the New England Journal of Medicine. […]
October 6th, 2014
This week’s topics include medical device safety and effectiveness, familial hypercholesterolemia, and more.
May 27th, 2014
This week’s topics include mortality trends in patients with diabetes, cardiovascular remodeling in CAD and HF, and more.